Trial
NCT06765954
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
ImmunityBio, Inc.
Collaborators
—
Condition
High-risk Prostate Cancer
Intervention
N-803 (IL-15 Superagonist)
Why stopped
Study was redeveloped into a new protocol
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-05